Breast Neoplasms
Conditions
Brief summary
This phase II trial studies the effectiveness of lapatinib ditosylate (lapatinib) together with trastuzumab in treating patients with HER2-negative breast cancer that carries HER2 gene mutations. Lapatinib may kill tumor cells by blocking some of the enzymes needed for cell division and growth. Trastuzumab, a monoclonal antibody, may block the ability of tumor cells to grow and spread. Giving lapatinib together with trastuzumab may provide a more effective treatment for patients with this type of cancer.
Interventions
DRUGlapatinib ditosylate
Given PO
BIOLOGICALtrastuzumab
Given IV
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must have histologically or cytologically confirmed metastatic breast cancer * The breast cancer has been tested negative for HER2 (0 or 1+ by immunohistochemistry \[IHC\] or non-amplified by fluorescence in-situ hybridization \[FISH\]) * Patient may have measurable or evaluable disease * If given prior radiotherapy and/or prior chemotherapy, the patient must have completed radiation therapy and be at least 1 week from the last chemotherapy administration, with adequate recovery of bone marrow and organ functions, before starting lapatinib or trastuzumab \* Note that the HER2 sequencing analysis can be performed while patient is receiving other systemic therapies so the results could be used to determine whether the patient is eligible to receive lapatinib and trastuzumab when disease progresses from current therapy * Patient must have had at least one lines of systemic therapy for metastatic breast cancer * Patient must have disease that progressed on his/her most recent treatment regimen * Patient must be \> 18 years of age. * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Total bilirubin =\< 1.5 x institutional upper limit of normal (IULN) unless due to Gilbert's syndrome * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 3.0 x IULN with/without liver metastases * Creatinine =\< 1.5 x IULN * Patient must have a left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal (ILLN) to be eligible for study treatment; to avoid the cost of screening, patients with known recent LVEF \< LLN or symptoms of congestive heart failure are not eligible for registration * Women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately * Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an institutional review board (IRB) approved written informed consent document * Patients with known treated brain metastasis are eligible, but must have received radiation and be off steroids and stable for 3 months * Patients meeting all inclusion criteria listed above and
Exclusion criteria
will be registered to undergo HER2 mutation analysis; only patients with mutations in HER2 either in the primary or metastatic tumor are eligible for study therapy with lapatinib and trastuzumab; those without mutations in HER2 are not eligible for study drug therapy; information and tissue collected from patients without HER2 mutations will be used for molecular epidemiology studies of HER2 negative breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall clinical benefit rate (CBR; CD + PR + SD) of lapatinib and trastuzumab in patients with breast cancer that carry HER2 mutations | 6 months | Responses assessed using RECIST guidelines version 1.1; duration of SD must be \>= 6 months; CBR and its 80% confidence interval will be calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer) | Baseline | — |
| Correlation of HER2 mutation with tumor grade (1-2 vs. 3) | Baseline | — |
| PFS of patients treated with lapatinib and trastuzumab | 2 years | Assessed using RECIST guidelines version 1.1 |
| Correlation of HER2 mutation with disease free survival | 2 years | — |
| Occurrence of HER2 mutation in paired primary and metastatic sites | Baseline | — |
| Correlation of HER2 mutation with tumor staging at initial diagnosis (I vs. II or III vs. IV) | Baseline | — |
Outcome results
None listed